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prospective cohort studies
JIM McCAMBRIDGE & GREG HARTWELL
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Abstract
Introduction And Aims. There have been no previous quantitative analyses of the possible effects of industry funding on
alcohol and health research.This study examines whether findings of alcohol’s protective effects on cardiovascular disease may
be biased by industry funding. Design and Methods.Findings from a recent systematic review of prospective cohort studies
were combined with public domain data on alcohol industry funding. The six outcomes evaluated were alcohol’s effects on
cardiovascular disease mortality, incident coronary heart disease, coronary heart disease mortality, incident stroke, stroke
mortality and mortality from all causes. Results.We find no evidence of possible funding effects for outcomes other than stroke.
Whether studies find alcohol to be a risk factor or protective against incident stroke depends on whether or not there is possible
industry funding [risk ratio (RR) 1.07 (0.97–1.17) for those without concern about industry funding compared with RR 0.88
(0.81–0.94)]. For stroke mortality, a similar difference is not statistically significant, most likely because there are too few
studies. Discussion and Conclusions.Dedicated high-quality studies of possible alcohol industry funding effects should be
undertaken, and these should be broad in scope.They also need to investigate specific areas of concern, such as stroke, in greater
depth. [McCambridge J, Hartwell G. Has industry funding biased studies of the protective effects of alcohol on
cardiovascular disease? A preliminary investigation of prospective cohort studies. Drug Alcohol Rev 2014]
Key words: alcohol, alcohol industry, bias, cardiovascular disease, health benefits.
Introduction
The apparent protective effects of alcohol on cardiovas-
cular and other diseases make it unlike other drugs,
such as tobacco. Concerns about the validity of these
findings, for example, in relation to misclassification
bias of formerly heavier drinkers who have stopped,
have existed for approximately 30 years [1,2]. In addi-
tion to the well-known problems implicit in making
causal inferences on the basis of observational data,
beyond cardiovascular disease many of the claimed
health benefits have no plausible biological mechanisms
nor obvious relationships to each other [3]. This is all
the more curious as reliable exposure measurement of
patterns of drinking over time is complex, and may be
weak in many of the primary studies [4]. A recurrent
finding in meta-analytic studies of alcohol’s protective
effects on cardiovascular disease is the striking levels of
unexplained heterogeneity between studies [5,6].
Disclosure of internal tobacco industry documents—
mandated by the courts during litigation in the USA—
has revealed a history of subversion of science spanning
decades [7]. It has previously been suggested that
alcohol industry-funded reviews are ‘those studies
which reported more enthusiastically about the poten-
tial cardio-protective nature of moderate alcohol use’
[1]. One recent ‘consensus document’ in this area
brings together a wide range of Italian medical and
academic bodies under the auspices of the Nutrition
Foundation of Italy, yet it does not identify the foun-
dation as an industry body in the paper, or contain any
declarations of conflicts of interest [8].
Substantial grounds for concern about industry
influence on alcohol research [9,10] have not led to
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quantitative investigations of possible funding effects.
We thus sought to examine whether findings from a
recent systematic review of prospective cohort studies
of alcohol’s protective effects on cardiovascular disease
may be biased by industry funding.
Methods
For this preliminary investigation, we examined a
recent systematic review of prospective cohort studies
[11] and obtained the primary reports of all 84
included studies. We were aware that, in the case of
tobacco, industry lawyers had routinely edited scientific
papers written by industry-funded scientists, deleting
acknowledgements of industry sponsorship [7]. In
addition to declarations of funding sources in the 84
reports themselves, we gathered data from industry
research funding websites (see Babor [10]), peer-
reviewed papers and other public domain data sources,
such as university websites, and contacted authors from
all papers for additional information [64/80 email
replies (80%), two papers no active email addresses
found, two papers all authors deceased].We categorised
individual studies as described in Box 1, double coding
blindly any study where there was any doubt about
categorisation. It will be seen that we assumed the
absence of any funding information (i.e. category 5) to
indicate no concern. As this is a questionable decision,
we undertook a sensitivity analysis to interrogate this
assumption. Our approach to possible industry funding
was not restricted to individual papers or to individual
authors; we took any evidence of industry funding for
any purpose at any time by any author (including
travel) and university receipt of any alcohol industry
funding for health research at any time to indicate some
level of concern.
Ronksley and colleagues [11] compared drinkers with
non-drinkers in prospective cohort studies and investi-
gated cardiovascular disease mortality, incident coro-
nary heart disease, coronary heart diseasemortality,
incident stroke, stroke mortality and all-cause mortality,
with subsets of studies providing data for each outcome.
We calculated relative risk estimates (presented as
effect size in the figures) and their confidence intervals
for the associations with alcohol consumption, pooled
in random effects models (using the method of
DerSimonian and Laird with the metan command in
stata; Statacorp LP, College Station,TX, USA) strati-
fied by level of concern about industry funding,as shown
in Box 1. We re-ran the metan command to test for
statistical significance of differences between strata.We
combined moderate and high levels of concern because
there were few instances of the latter for some outcomes
and ran the analyses for both the two (some concern vs.
no concern) and three (no, moderate and high levels of
concern) groups of studies. For presentational reasons,
we offer the data for the some versus no concern contrast
as there was generally little difference in outcomes
between the studies with high levels of concern about
industry funding and those categorised as moderate
concern. For the sensitivity analysis, we investigated the
effect of the absence of information (category ‘5’) being
taken as constituting some level of concern rather than
no concern.This left the ‘no concern’category to include
only those studies where some specific evidence existed
for a lack of industry funding (e.g. assurances received
from the author ruling out industry funding or a decla-
ration in the paper itself of non-industry-funding
sources).
Box 1. Levels of concern about industry funding of research
High level of concern
1. Declaration in paper of industry funding of study being reported
2. Any evidence of any author in receipt of undeclared industry funding (from publicly available data sources)
Moderate level of concern
3. Declaration in paper of any author in receipt of industry funding for any other purpose, such as travel, at any time
4. Any evidence of institutional funding concerns (i.e. industry funding health-related studies by other researchers in the
same institution of any author, from publicly available data sources) at any time
No concern
5. No funding information in paper, nor replied to email seeking further information
6. No funding information in paper, replied to give assurances ruling out industry funding
7. Declaration in paper of non-industry funding sources, no reply to email seeking further information
8. Declaration in paper of non-industry funding sources, replied to give assurances ruling out industry funding
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Results
There is no evidence of funding effects for cardiovas-
cular disease mortality, incident coronary heart disease,
coronary heart disease mortality and all-cause mortal-
ity, and these data are presented in Figures 1–4.
Concern about industry funding is, however, associated
with observed outcomes for stroke. Alcohol consump-
tion is found to be protective against stroke incidence in
the group of eight studies where there is concern about
industry funding, whereas it is found to be a risk factor
in the group of 10 studies where concern about indus-
try funding is absent, with little heterogeneity within
the two groups; see Figure 5. Differences between these
pooled effects are statistically significant [χ2 = 9.75
(1 d.f.) P = 0.002].
When splitting the high and moderate levels of
concern for the stroke incidence findings, we found that
the pooled effects for the two studies with high levels of
concern about industry funding were somewhat less
discrepant from the studies with no concern compared
with those with moderate levels of concern [risk ratio
(RR) 0.92 (0.79–1.05) compared with RR 0.86 (0.79–
0.93)]. For the sensitivity analysis, whereby category ‘5’
was taken as constituting some level of concern rather
than no concern, no differences were observed in the
point estimates presented in Figure 5. This applied
both to the analyses comparing some concern with no
concern and to those when the groups were split into
moderate and high levels of concern, with only minor
changes to confidence intervals in each instance.
Although there are few studies of stroke mortality
and only two with funding concerns, a similar pattern is
apparent in the pooled relative risk estimates for that
outcome (see Figure 6). The difference is not statisti-
cally significant [χ2 = 1.94 (1 d.f.), P = 0.163].
.
.
Overall  (I-squared = 76.3%, P = 0.000)
Fuchs (1995)
Kono (1986)
Cullen (1993)
Renaud (1999)
Subtotal  (I-squared = 81.7%, P = 0.000)
ID
Gronbaek (1995)
Trevisan (2001)
Xu (2007)
Djousse (2009)
Scherr (1992)
NO CONCERN
Jamrozik (2000)
Knoops (2004)
Subtotal  (I-squared = 74.1%, P = 0.000)
Lin (2005)
Kivela (1989)
Berberian (1994)
Klatsky (1990)
Study
Deev (1998): Russia cohort
Gaziano (2000)
Thun (1997)
Harriss (2007)
Waskiewicz (2004)
Deev (1998): USA cohort
SOME CONCERN
Bazzano (2009)
0.74 (0.69, 0.79)
0.69 (0.61, 0.79)
0.97 (0.82, 1.14)
0.77 (0.65, 0.92)
0.81 (0.67, 0.97)
0.75 (0.66, 0.83)
ES (95% CI)
0.79 (0.68, 0.93)
0.60 (0.45, 0.79)
0.80 (0.60, 0.90)
0.94 (0.69, 1.28)
0.77 (0.50, 1.18)
0.47 (0.30, 0.77)
0.74 (0.59, 0.93)
0.73 (0.66, 0.81)
0.86 (0.62, 1.20)
0.91 (0.63, 1.32)
0.42 (0.24, 0.73)
0.81 (0.73, 0.90)
0.79 (0.66, 0.94)
0.80 (0.74, 0.86)
0.71 (0.68, 0.75)
1.07 (0.72, 1.59)
0.54 (0.44, 0.68)
0.49 (0.40, 0.59)
0.83 (0.78, 0.89)
100.00
6.35
4.53
5.15
4.77
40.09
Weight
5.41
4.29
4.77
2.25
1.83
3.04
4.29
59.91
2.31
1.79
2.89
6.48
%
5.02
7.09
7.55
1.23
5.55
6.22
7.20
Figure 1. Cardiovascular disease (CVD) mortality findings by concern about industry funding. CI, confidence interval.
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Discussion
This study gives no specific grounds for concern that
alcohol industry funding has biased what is known
about the protective effects of alcohol on cardiovascular
disease, apart from with regard to stroke. Our investi-
gation provides evidence that findings from studies
evaluating associations between alcohol consumption
and incident stroke vary considerably according to
whether or not there is concern about industry funding.
This difference is unlikely to have arisen by chance,
even allowing for multiplicity of analyses and even
though similar evidence was absent for other cardio-
protective outcomes. This set of findings provides
grounds for a more generalised concern that there is a
need to evaluate further whether observed heterogene-
ity among studies of the health benefits of alcohol may
be in part due to industry funding. The data patterns
described here are curious as it is not obvious prima
facie why findings for stroke might be discrepant from
other possible protective effects on cardiovascular
disease outcomes.
This study has clear limitations. It is a brief review of
published findings in this literature as a whole, and no
attempt has been made at this stage to investigate the
detailed content of individual primary studies. The
validity of the findings is contingent upon correct clas-
sification of funding concern, and our measure is
neither validated nor capable of detecting well-hidden
funding. It incorporates relatively trivial associations
with industry, for example, one author only having
accepted travel support at some time previously, or one
.
.
Overall  (I-squared = 69.6%, P = 0.000)
Camargo (1997)
Hammar (1997)
Salonen (1983)
Simons (1996)
Marques-Vidal (2004): French cohort
Tolstrup (2006)
SOME CONCERN
Subtotal  (I-squared = 69.1%, P = 0.000)
Wilkins (2002)
Kitamura (1998)
Mukamal (2003)
Gordon (1983)
Mukamal (2006)
Ebrahim (2008): Caerphilly cohort
Ikehara (2009)
NO CONCERN
Shaper (1987)
Kittner (1983)
Fuchs (2004)
ID
Murray (2002)
Yang (1999)
Klatsky (1997)
Hein (1996)
Ebrahim (2008): WHHS cohort
Wellman (2004)
Burke (2007)
Manttari (1997)
Iso (1995)
Murray (2005)
Marques-Vidal (2004): Irish cohort
Study
Gordon (1985)
Solomon (2000)
Rehm (1997)
Bazzano (2009)
Subtotal  (I-squared = 54.1%, P = 0.004)
0.69 (0.63, 0.75)
0.78 (0.63, 0.98)
0.66 (0.48, 0.92)
0.54 (0.21, 1.38)
0.86 (0.74, 0.99)
0.55 (0.40, 0.74)
0.69 (0.62, 0.76)
0.66 (0.53, 0.78)
0.84 (0.35, 1.98)
0.56 (0.39, 0.80)
0.77 (0.65, 0.92)
0.74 (0.65, 0.84)
0.80 (0.65, 0.98)
0.88 (0.47, 1.65)
0.33 (0.24, 0.46)
1.06 (0.53, 2.13)
0.66 (0.50, 0.85)
0.85 (0.54, 1.34)
ES (95% CI)
0.80 (0.45, 1.44)
0.30 (0.20, 0.60)
0.78 (0.71, 0.85)
0.61 (0.41, 0.91)
0.80 (0.53, 1.22)
0.47 (0.33, 0.67)
1.70 (1.10, 2.63)
0.77 (0.46, 1.29)
0.83 (0.48, 1.45)
0.80 (0.67, 0.96)
0.77 (0.57, 1.04)
0.72 (0.59, 0.86)
0.63 (0.38, 1.05)
0.67 (0.59, 0.76)
0.73 (0.54, 0.98)
0.72 (0.67, 0.77)
100.00
4.05
3.37
0.89
4.88
4.13
5.72
35.20
0.49
3.58
4.71
5.36
4.21
0.88
5.13
0.51
4.05
1.64
Weight
1.18
3.66
5.72
2.97
2.02
4.13
0.56
1.55
1.22
4.54
3.16
%
4.71
2.10
5.51
3.37
64.80
Figure 2. Coronary heart disease (CHD) incidence findings by concern about industry funding. CI, confidence interval.
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institution having received alcohol industry funding for
health research long ago. Note that covert funding will
also have led to some misclassification bias, systemati-
cally biasing observed associations towards the null.We
have not addressed the year of publication, and stand-
ards for declarations of conflicts of interest have clearly
evolved over time [12]. It was not possible to investigate
directly whether previously observed differences in the
alcohol risk functions for haemorrhagic stroke (i.e. dose
response) and ischemic stroke (j-shaped) for both mor-
bidity and mortality [13] may be partly because of
funding effects. Studies where there is concern about
industry funding tend to have larger sample sizes than
those which do not, and there is evidence that larger
studies tend to be less biased [14]. There is also some
suggestion of publication bias among those studies
included here for which there is no concern about
industry funding, as no small studies show strongly
protective effects.
The lack of prior quantitative study of the alcohol
industry’s possible involvement in subversion of science
is somewhat surprising [15], given the existence of
funding effects is well established,particularly in relation
to pharmaceutical companies [16]. Studies indicate that
such funding effects are carefully and subtly manufac-
tured by pharmaceutical corporations, selecting certain
.
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Figure 3. Coronary heart disease (CHD) mortality findings by concern about industry funding. CI, confidence interval.
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high-quality primary studies for publication in leading
journals and not disclosing others [17]. Funding effects
have also been found to bias conclusions in favour of
industry in the field of nutrition [18].There are numer-
ous decisions made in the conduct of any study with
potential to bias findings in one direction or another, and
such practices are much more difficult to detect than
‘shoddy studies done by mercenary researchers who
manipulated methods and data’ [16] as was once
believed to be the nature of the influence of corporate
funding on health research. Despite sustained efforts in
recent years, there has been a limited progress made in
the reporting of conflicts of interest in drug trials [19],
and progress on observational epidemiological studies
should also be expected to be slow, unless actions are
taken to accelerate this process.
The alcohol industry is known to have made exten-
sive efforts to subvert the use of science by policy
makers [9,10,20–23]. We do not know whether the
alcohol industry has behaved like the tobacco industry
in perpetrating a decades-long conspiracy to subvert
the peer-reviewed science base itself [24], though it is
important to consider such possibilities.The similarities
in the strategic problems faced by both industries are
.
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Figure 4. All-cause mortality findings by concern about industry funding. CI, confidence interval.
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striking [25]: they produce legally available and widely
used drugs that will damage the health of, and ulti-
mately kill, significant proportions of their users. It
would be surprising if the alcohol industry had ignored
the subversion of science as a vehicle for advancing
corporate interests, particularly in light of evidence of
cross ownership of the tobacco and alcohol industries
[26], leading to direct tobacco industry influence on the
formation of globally significant alcohol industry strat-
egies [20]. Furthermore, the two industries have previ-
ously been found to have worked closely together to
thwart the introduction of evidence-based policy meas-
ures [27].
This study is designated as preliminary because we
suggest it is important to undertake further more
sophisticated investigations of the issues covered.
Dedicated studies of alcohol industry funding effects
can build upon previous work on corporate corruption
of science. Investigations of the detailed content of
primary studies to identify which, if any, study decisions
may be responsible for biasing the health benefits of
alcohol should be useful. Although challenging because
of the nature of the measurement target, it will be
necessary to develop finer-grained reliable measures of
industry funding for use in quantitative studies. These
could, for example, separately assess the various
components we have combined here, such as indivi-
dual travel and institutional acceptance of funding.
Measures which rely upon self-disclosure should clearly
note this as a limitation, despite the stringent and
sophisticated efforts of journals to enhance transpar-
ency by addressing the complexities of conflicts of
interest [12]. Studies of funding effects should be broad
in scope, investigating where the alcohol industry
spends its money on research and where it does not.We
are unaware of any significant attention given in the
peer-reviewed evidence base to internal alcohol indus-
try research programs [10]. This should be rectified.
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Figure 5. Stroke incidence findings by concern about industry funding. CI, confidence interval; HPFUS, Health Professionals
Follow-Up Study.
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Experience with the tobacco industry indicates that
areas of uncertainty with potential to alter perceptions
held by policy makers, as was the case with passive
smoking [16], may be of particular interest. For the
outcomes investigated here, other than stroke incidence
and mortality, alcohol’s health benefits appear less
likely to have been compromised by funding effects.
This study is not designed to assess the validity of these
findings, but it may be that funding effects are more
likely to exist for stroke because the effects of alcohol on
stroke outcomes are more uncertain.
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